Literature DB >> 19155101

Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer.

Ronald L Klein1, Robert D Dayton, Cynthia G Diaczynsky, David B Wang.   

Abstract

Microtubule-associated protein tau gene transfer to the substantia nigra of rats using the adeno-associated virus (AAV) vector previously led to neuropathology and neurodegeneration in young rats. In this study, we compared equal tau gene transfer in either 3 or 20-month-old rats, in order to test the hypothesis that late middle-aged rats are more susceptible to neurodegeneration. Two intervals and two vector doses of the tau vector probed for age-related differences in the initial sensitivity to low-level tau expression. Gene transfer efficiency was similar for both ages, but the tau vector caused more dopaminergic cell loss and a greater behavioral deficit in aged rats at specific doses and time points. Tau gene transfer caused microgliosis relative to the control vector, and to a greater extent in aged rats. The maximal microglial response occurred at 2 weeks preceding the peak dopaminergic cell loss by 8 weeks. The cellular and behavioral outcomes were more severe in the aged rats, validating the model for studies of age-related diseases.
Copyright © 2008 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155101      PMCID: PMC2975326          DOI: 10.1016/j.neurobiolaging.2008.12.002

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  36 in total

1.  Enhanced effects of 6-hydroxydopamine on evoked overflow of striatal dopamine in aged rats.

Authors:  Wayne A Cass; Michael E Harned; Sherry L Bailey
Journal:  Brain Res       Date:  2002-05-31       Impact factor: 3.252

2.  How old is old?

Authors:  Paul D Coleman
Journal:  Neurobiol Aging       Date:  2004-01       Impact factor: 4.673

3.  Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra.

Authors:  Ronald L Klein; Michael A King; Mary E Hamby; Edwin M Meyer
Journal:  Hum Gene Ther       Date:  2002-03-20       Impact factor: 5.695

4.  Improved detection of substantia nigra pathology in Alzheimer's disease.

Authors:  Julie A Schneider; Julia L Bienias; David W Gilley; David E Kvarnberg; Elliott J Mufson; David A Bennett
Journal:  J Histochem Cytochem       Date:  2002-01       Impact factor: 2.479

5.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Progressive reduction of synaptophysin message in single neurons in Alzheimer disease.

Authors:  Linda M Callahan; William A Vaules; Paul D Coleman
Journal:  J Neuropathol Exp Neurol       Date:  2002-05       Impact factor: 3.685

7.  Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice.

Authors:  Shuei Sugama; Lichuan Yang; Byung Pil Cho; Lorraine A DeGiorgio; Stefan Lorenzl; David S Albers; M Flint Beal; Bruce T Volpe; Tong H Joh
Journal:  Brain Res       Date:  2003-02-28       Impact factor: 3.252

8.  Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.

Authors:  Stephen K Van Den Eeden; Caroline M Tanner; Allan L Bernstein; Robin D Fross; Amethyst Leimpeter; Daniel A Bloch; Lorene M Nelson
Journal:  Am J Epidemiol       Date:  2003-06-01       Impact factor: 4.897

9.  An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.

Authors:  Parvoneh Poorkaj; Nancy A Muma; Victoria Zhukareva; Elizabeth J Cochran; Kathleen M Shannon; Howard Hurtig; William C Koller; Thomas D Bird; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg
Journal:  Ann Neurol       Date:  2002-10       Impact factor: 10.422

10.  Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy.

Authors:  E Di Maria; M Tabaton; T Vigo; G Abbruzzese; E Bellone; C Donati; E Frasson; R Marchese; P Montagna; D G Munoz; P P Pramstaller; G Zanusso; F Ajmar; P Mandich
Journal:  Ann Neurol       Date:  2000-03       Impact factor: 10.422

View more
  20 in total

1.  Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response.

Authors:  David B Wang; Robert D Dayton; Richard M Zweig; Ronald L Klein
Journal:  Exp Neurol       Date:  2010-03-24       Impact factor: 5.330

2.  Focal expression of mutated tau in entorhinal cortex neurons of rats impairs spatial working memory.

Authors:  Julio J Ramirez; Winona E Poulton; Erik Knelson; Cole Barton; Michael A King; Ronald L Klein
Journal:  Behav Brain Res       Date:  2010-08-19       Impact factor: 3.332

3.  Isocitrate dehydrogenase 1 is downregulated during early skin tumorigenesis which can be inhibited by overexpression of manganese superoxide dismutase.

Authors:  Delira Robbins; Jennifer A Wittwer; Sarah Codarin; Magdalena L Circu; Tak Yee Aw; Ting-Ting Huang; Holly Van Remmen; Arlan Richardson; David B Wang; Stephan N Witt; Ronald L Klein; Yunfeng Zhao
Journal:  Cancer Sci       Date:  2012-06-07       Impact factor: 6.716

Review 4.  Versatile somatic gene transfer for modeling neurodegenerative diseases.

Authors:  Ronald L Klein; David B Wang; Michael A King
Journal:  Neurotox Res       Date:  2009-08-11       Impact factor: 3.911

5.  Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain.

Authors:  Nicole K Polinski; Sara E Gombash; Fredric P Manfredsson; Jack W Lipton; Christopher J Kemp; Allyson Cole-Strauss; Nicholas M Kanaan; Kathy Steece-Collier; Nathan C Kuhn; Susan L Wohlgenant; Caryl E Sortwell
Journal:  Neurobiol Aging       Date:  2014-10-13       Impact factor: 4.673

Review 6.  Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues.

Authors:  Lars M Ittner; Matthias Klugmann; Yazi D Ke
Journal:  Br J Pharmacol       Date:  2019-04-23       Impact factor: 8.739

7.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016

8.  Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease.

Authors:  Tomasz Jaworski; Sebastian Kügler; Fred Van Leuven
Journal:  Int J Alzheimers Dis       Date:  2010-08-24

9.  Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain.

Authors:  Raphaëlle Caillierez; Séverine Bégard; Katia Lécolle; Vincent Deramecourt; Nadège Zommer; Simon Dujardin; Anne Loyens; Noëlle Dufour; Gwennaëlle Aurégan; Joris Winderickx; Philippe Hantraye; Nicole Déglon; Luc Buée; Morvane Colin
Journal:  Mol Ther       Date:  2013-04-23       Impact factor: 11.454

10.  AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice.

Authors:  Tomasz Jaworski; Ilse Dewachter; Benoit Lechat; Sophie Croes; Annelies Termont; David Demedts; Peter Borghgraef; Herman Devijver; Robert K Filipkowski; Leszek Kaczmarek; Sebastian Kügler; Fred Van Leuven
Journal:  PLoS One       Date:  2009-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.